{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:45:59Z","timestamp":1789681559338,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Province Health industry Science and Technology Plan","award":["2025HY0868"],"award-info":[{"award-number":["2025HY0868"]}]},{"name":"the Natural Science Foundation of Ningbo","award":["2024J337"],"award-info":[{"award-number":["2024J337"]}]},{"name":"Ningbo Municipal Program for Innovative and Leading Talents","award":["2024QL025"],"award-info":[{"award-number":["2024QL025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10495-026-02391-2","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:35:42Z","timestamp":1787502942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K\/AKT and ERK signaling pathways"],"prefix":"10.1007","volume":"31","author":[{"given":"Xiaodong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningbo","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"issue":"6","key":"2391_CR1","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/curroncol28060456","volume":"28","author":"MF Mohammed Saleh","year":"2021","unstructured":"Mohammed Saleh, M.F., et al., Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma. Curr Oncol, 2021. 28(6): p. 5480-5498.","journal-title":"Curr Oncol"},{"key":"2391_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101270","volume":"82","author":"C Wang","year":"2025","unstructured":"Wang, C., et al., TRIM24 promotes T-cell lymphoma development and glucocorticoid resistance via FUS-mediated phase separation of the glucocorticoid receptor. Drug Resist Updat, 2025. 82: p. 101270.","journal-title":"Drug Resist Updat"},{"key":"2391_CR3","doi-asserted-by":"publisher","first-page":"1683550","DOI":"10.3389\/fimmu.2025.1683550","volume":"16","author":"L Huang","year":"2025","unstructured":"Huang, L., et al., Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed\/refractory peripheral T cell lymphoma. Front Immunol, 2025. 16: p. 1683550.","journal-title":"Front Immunol"},{"issue":"48","key":"2391_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2504195122","volume":"122","author":"A Gui","year":"2025","unstructured":"Gui, A., et al., USP1-TRAF2 axis-regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma. Proc Natl Acad Sci U S A, 2025. 122(48): p. e2504195122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2391_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","volume":"12","author":"P Zhang","year":"2020","unstructured":"Zhang, P. and M. Zhang, Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics, 2020. 12(1): p. 169.","journal-title":"Clin Epigenetics"},{"key":"2391_CR6","doi-asserted-by":"crossref","unstructured":"Angelova, A., J. Rommelaere, and G. Ungerechts, The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics. Pathogens, 2024.13(3).","DOI":"10.3390\/pathogens13030184"},{"key":"2391_CR7","doi-asserted-by":"crossref","unstructured":"Tan, B.J., et al., HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia\/lymphoma. J Clin Invest, 2021. 131(24).","DOI":"10.1172\/JCI150472"},{"key":"2391_CR8","doi-asserted-by":"publisher","first-page":"1430648","DOI":"10.3389\/fimmu.2024.1430648","volume":"15","author":"X Zong","year":"2024","unstructured":"Zong, X., et al., Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma. Front Immunol, 2024. 15: p. 1430648.","journal-title":"Front Immunol"},{"issue":"9","key":"2391_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamadermatol.2025.1926","volume":"161","author":"Z Pang","year":"2025","unstructured":"Pang, Z., et al., Linperlisib Plus Chidamide in Relapsed or Refractory Cutaneous T-Cell Lymphoma: A Nonrandomized Clinical Trial. JAMA Dermatol, 2025. 161(9): p. 923-930.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2391_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/blood.2024027902","volume":"146","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu, M., et al., A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia\/lymphoma. Blood, 2025. 146(12): p. 1440-1449.","journal-title":"Blood"},{"issue":"10","key":"2391_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.tips.2016.06.010","volume":"37","author":"Z Liu","year":"2016","unstructured":"Liu, Z., et al., Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. Trends in Pharmacological Sciences, 2016. 37(10): p. 843-857.","journal-title":"Trends in Pharmacological Sciences"},{"issue":"12","key":"2391_CR12","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1038\/s41591-024-03233-x","volume":"30","author":"K Huang","year":"2024","unstructured":"Huang, K., et al., A foundation model for clinician-centered drug repurposing. Nat Med, 2024. 30(12): p. 3601-3613.","journal-title":"Nat Med"},{"issue":"12","key":"2391_CR13","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/bph.16036","volume":"180","author":"W Li","year":"2023","unstructured":"Li, W., et al., Discovery of alantolactone as a naturally occurring NLRP3 inhibitor to alleviate NLRP3-driven inflammatory diseases in mice. Br J Pharmacol, 2023. 180(12): p. 1634-1647.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2391_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12985-025-02759-x","volume":"22","author":"X Wu","year":"2025","unstructured":"Wu, X., et al., Inhibitory effect of Alantolactone against varicella-zoster virus in vitro. Virol J, 2025. 22(1): p. 138.","journal-title":"Virol J"},{"key":"2391_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2025.106716","volume":"185","author":"S Thakur","year":"2025","unstructured":"Thakur, S., et al., Insights to phytochemistry, analytical methods, pharmacological activities, stability, and specifications of alantolactone. Fitoterapia, 2025. 185: p. 106716.","journal-title":"Fitoterapia"},{"key":"2391_CR16","doi-asserted-by":"crossref","unstructured":"Wang, H., et al., Screening of Traditional Chinese Medicine Compounds Identified the Anti-Helicobacter pylori Effects of Alantolactone, Decursin, and Phillygenin. J Infect Dis, 2025. 232(Supplement_4): p. S397-S411.","DOI":"10.1093\/infdis\/jiaf426"},{"issue":"1","key":"2391_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41387-024-00300-7","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang, J., et al., Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease. Nutr Diabetes, 2024. 14(1): p. 41.","journal-title":"Nutr Diabetes"},{"key":"2391_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.847906","volume":"13","author":"Z Fu","year":"2022","unstructured":"Fu, Z., et al., Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer. Front Pharmacol, 2022. 13: p. 847906.","journal-title":"Front Pharmacol"},{"key":"2391_CR19","doi-asserted-by":"crossref","unstructured":"van Duijn, A., S.H. Van der Burg, and F.A. Scheeren, CD47\/SIRPalpha axis: bridging innate and adaptive immunity. J Immunother Cancer, 2022. 10(7).","DOI":"10.1136\/jitc-2022-004589"},{"issue":"1","key":"2391_CR20","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-025-59621-5","volume":"16","author":"P Dai","year":"2025","unstructured":"Dai, P., et al., USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity. Nat Commun, 2025. 16(1): p. 4564.","journal-title":"Nat Commun"},{"issue":"2","key":"2391_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jhep.2022.03.011","volume":"77","author":"S Wang","year":"2022","unstructured":"Wang, S., et al., Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model. J Hepatol, 2022. 77(2): p. 467-478.","journal-title":"J Hepatol"},{"issue":"8016","key":"2391_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter, S.A., et al., Engineered CD47 protects T cells for enhanced antitumour immunity. Nature, 2024. 630(8016): p. 457-465.","journal-title":"Nature"},{"issue":"1","key":"2391_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang, N., et al., Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun, 2022. 13(1): p. 1511.","journal-title":"Nat Commun"},{"issue":"3","key":"2391_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41375-019-0622-6","volume":"34","author":"H Kamijo","year":"2020","unstructured":"Kamijo, H., et al., Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia, 2020. 34(3): p. 845-856.","journal-title":"Leukemia"},{"issue":"10","key":"2391_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107785","volume":"300","author":"L Sun","year":"2024","unstructured":"Sun, L., et al., Nucleolin malonylation as a nuclear-cytosol signal exchange mechanism to drive cell proliferation in Hepatocarcinoma by enhancing AKT translation. J Biol Chem, 2024. 300(10): p. 107785.","journal-title":"J Biol Chem"},{"issue":"6","key":"2391_CR26","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/febs.15541","volume":"288","author":"MU Thomas","year":"2021","unstructured":"Thomas, M.U., et al., Macrophages expedite cell proliferation of prostate intraepithelial neoplasia through their downstream target ERK. FEBS J, 2021. 288(6): p. 1871-1886.","journal-title":"FEBS J"},{"key":"2391_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109439","volume":"65","author":"J Zhao","year":"2020","unstructured":"Zhao, J., et al., Betacellulin enhances ovarian cancer cell migration by up-regulating Connexin43 via MEK-ERK signaling. Cell Signal, 2020. 65: p. 109439.","journal-title":"Cell Signal"},{"issue":"12","key":"2391_CR28","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1038\/s41375-024-02401-9","volume":"38","author":"BS Willis","year":"2024","unstructured":"Willis, B.S., et al., Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia, 2024. 38(12): p. 2663-2674.","journal-title":"Leukemia"},{"issue":"11","key":"2391_CR29","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1007\/s00277-025-06571-z","volume":"104","author":"X Li","year":"2025","unstructured":"Li, X., et al., Targeting the akt\/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma. Ann Hematol, 2025. 104(11): p. 5841-5854.","journal-title":"Ann Hematol"},{"issue":"1","key":"2391_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13148-026-02056-6","volume":"18","author":"J Lin","year":"2026","unstructured":"Lin, J., et al., Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K\/AKT inhibition. Clin Epigenetics, 2026. 18(1): p. 34.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2391_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-024-03145-1","volume":"43","author":"Q Luo","year":"2024","unstructured":"Luo, Q., et al., LINC00460\/miR-186-3p\/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions. J Exp Clin Cancer Res, 2024. 43(1): p. 225","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2391_CR32","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/cas.14849","volume":"112","author":"N Yoshida","year":"2021","unstructured":"Yoshida, N., K. Yamada, and K. Ohshima, Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. Cancer Sci, 2021. 112(4): p. 1339-1347.","journal-title":"Cancer Sci"},{"key":"2391_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111231","volume":"136","author":"G Babaei","year":"2021","unstructured":"Babaei, G., et al., A comprehensive review of anticancer mechanisms of action of Alantolactone. Biomed Pharmacother, 2021. 136: p. 111231.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2391_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12931-020-01358-4","volume":"21","author":"X Dang","year":"2020","unstructured":"Dang, X., et al., Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2\/HO-1 and inhibition of the NF-kappaB pathways. Respir Res, 2020. 21(1): p. 95.","journal-title":"Respir Res"},{"key":"2391_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jare.2024.04.033","volume":"65","author":"Y Wu","year":"2024","unstructured":"Wu, Y., et al., Sodium citrate targeting Ca(2+)\/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer. J Adv Res, 2024. 65: p. 89-104.","journal-title":"J Adv Res"},{"issue":"1","key":"2391_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12916-023-02904-9","volume":"21","author":"J Wu","year":"2023","unstructured":"Wu, J., et al., PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer\/T cell lymphoma. BMC Med, 2023. 21(1): p. 253.","journal-title":"BMC Med"},{"issue":"7","key":"2391_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70286","volume":"18","author":"C Fernandez Teruel","year":"2025","unstructured":"Fernandez Teruel, C., et al., Population Pharmacokinetics and Exposure-Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer. Clin Transl Sci, 2025. 18(7): p. e70286.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2391_CR38","doi-asserted-by":"publisher","first-page":"11111","DOI":"10.1038\/s41467-025-66087-y","volume":"16","author":"Y Huang","year":"2025","unstructured":"Sigaud, R., et al., The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro Oncol, 2023. 25(3): p. 566-579.","journal-title":"Nat Commun"},{"issue":"2","key":"2391_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Huang, Y., et al., Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. Nat Commun, 2025. 16(1): p. 11111.","journal-title":"Nat Med"},{"issue":"5","key":"2391_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood.2024025277","volume":"145","author":"J Ma","year":"2025","unstructured":"Theruvath, J., et al., Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med, 2022. 28(2): p. 333-344.","journal-title":"Blood"},{"key":"2391_CR41","doi-asserted-by":"crossref","unstructured":"Ma, J., et al., Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood, 2025. 145(5): p. 508-519.","DOI":"10.1182\/blood.2024025277"},{"issue":"1","key":"2391_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.2021014485","volume":"140","author":"K Muller","year":"2022","unstructured":"Han, Z., et al., Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma. J Invest Dermatol, 2023. 143(8): p. 1569-1578 e5.","journal-title":"Blood"},{"issue":"6","key":"2391_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Muller, K., et al., Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood, 2022. 140(1): p. 45-57.","journal-title":"Blood Rev"},{"issue":"5","key":"2391_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","volume":"30","author":"AS Folkes","year":"2018","unstructured":"Russ, A., et al., Blocking \"don't eat me\" signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev, 2018. 32(6): p. 480-489.","journal-title":"Curr Opin Oncol"},{"key":"2391_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2026.101385","volume":"86","author":"P Wang","year":"2026","unstructured":"Folkes, A.S., et al., Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience. Curr Opin Oncol, 2018. 30(5): p. 332-337.","journal-title":"Drug Resist Updat"},{"key":"2391_CR46","doi-asserted-by":"crossref","unstructured":"Wang, P., et al., The c-Myc-USP14-PFKP axis sustains chemoresistance in pancreatic ductal adenocarcinoma. Drug Resist Updat, 2026. 86: p. 101385.","DOI":"10.1016\/j.drup.2026.101385"},{"key":"2391_CR47","doi-asserted-by":"crossref","unstructured":"Wahnschaffe, L., et al., Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression. Nat Commun, 2026. 17(1).","DOI":"10.1038\/s41467-026-70185-w"},{"issue":"1","key":"2391_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12964-025-02376-9","volume":"23","author":"L Nawale","year":"2025","unstructured":"Tanimoto, A., et al., The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC. J Thorac Oncol, 2025.","journal-title":"Cell Commun Signal"},{"key":"2391_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117761","volume":"247","author":"A Guo","year":"2026","unstructured":"Nawale, L., et al., ATE1 promotes breast cancer progression via arginylation-dependent regulation of MAPK-MYC signaling. Cell Commun Signal, 2025. 23(1): p. 390.","journal-title":"Biochem Pharmacol"},{"key":"2391_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101332","volume":"85","author":"D Tan","year":"2025","unstructured":"Guo, A., et al., Momordin Ic suppresses breast cancer growth by targeting ACTL8\u2011dependent glutamine metabolism and PI3K\/AKT\/mTOR-MYC. Biochem Pharmacol, 2026. 247: p. 117761.","journal-title":"Drug Resist Updat"},{"key":"2391_CR51","doi-asserted-by":"crossref","unstructured":"Tan, D., et al., UBL3 governs VEGFR inhibitor resistance by activating NOTCH signaling in renal cell carcinoma. Drug Resist Updat, 2025. 85: p. 101332.","DOI":"10.1016\/j.drup.2025.101332"},{"key":"2391_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218210","volume":"639","author":"K Zhu","year":"2025","unstructured":"Bueloni, B., et al., Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications. Gut, 2025.","journal-title":"Cancer Lett"},{"key":"2391_CR53","volume":"50","author":"MC Cai","year":"2024","unstructured":"Zhu, K., et al., lncDDR suppresses drug resistance by regulating DNA damage repair through ILF2-YB1 in T-cell acute lymphoblastic leukemia. Cancer Lett, 2025. 639: p. 218210.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"2391_CR54","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00277-025-06271-8","volume":"104","author":"M Meng","year":"2025","unstructured":"Cai, M.C., et al., Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial. Lancet Reg Health West Pac, 2024. 50: p. 101160.","journal-title":"Ann Hematol"},{"key":"2391_CR55","doi-asserted-by":"crossref","unstructured":"Meng, M., et al., Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma. Ann Hematol, 2025. 104(3): p. 1747-1756.","DOI":"10.1007\/s00277-025-06271-8"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02391-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:10:01Z","timestamp":1789672201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02391-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8529840\/v1","asserted-by":"object"}]},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. Figure\u00a0\n                      \n                      C, Fig.\u00a0\n                      \n                      A, and Fig.\u00a0\n                      \n                      were drawn using BioGDP.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with protocols approved by the Animal Experimentation Ethics Committee of Zhejiang University of Chinese Medicine (Approval code: IACUC-202501\u201317).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"213"}}